Gene Augmentation and Editing to Improve TCR Engineered T Cell Therapy against Solid Tumors

Area of Science:

• Immunology
• Oncology
• Gene Therapy

Background:

• Chimeric antigen receptor T (CAR-T) and recombinant T cell receptor engineered T (rTCR-T) cells offer new cancer treatment avenues, particularly for hematological malignancies.
• Solid tumors present unique challenges, including immunosuppressive microenvironments, stromal barriers, and tumor heterogeneity, which limit T cell effectiveness.
• Current rTCR-T cell strategies require optimization for enhanced functionality, safety, and tumor infiltration to treat solid tumors effectively.

Purpose of the Study:

• To review recent advancements in rTCR-T cell therapy for solid tumors, focusing on improving functionality and safety.
• To provide an overview of ongoing clinical trials investigating rTCR-T cell therapy for solid tumors.
• To highlight the potential of gene therapy and gene editing in overcoming challenges associated with solid tumor treatment.

Main Methods:

• Selection of appropriate tumor-associated antigens for targeted therapy.
• Efficient delivery of optimized recombinant TCR transgenes into T cells.
• Gene editing techniques to eliminate endogenous TCR expression and disrupt inhibitory pathways.
• Engineering T cells with cytokines, chemokines, or targeting tumor stroma to enhance infiltration.
• Incorporation of safety switches to mitigate potential toxicities.

Main Results:

• Optimized rTCR-T cell design can improve T cell reactivity, functionality, and infiltration into solid tumors.
• Gene editing strategies can enhance the persistence and efficacy of adoptively transferred T cells.
• Targeting tumor stroma and incorporating safety mechanisms can improve treatment safety and efficacy.
• Ongoing clinical trials show encouraging results for rTCR-T cell therapy in solid tumors.

Conclusions:

• rTCR-T cell therapy holds significant potential for treating solid tumors, building on successes in hematological malignancies.
• Further advancements in gene engineering, including gene editing and safety switch incorporation, are crucial for optimizing rTCR-T cell therapy.
• Clinical trials are demonstrating the feasibility and promise of these advanced T cell therapies for solid tumor treatment.